Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Phase I results of a novel FGFR inhibitor

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.16
Views: 1396

Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland

Dr Joerger speaks with ecancertv at ESMO 2016 about a novel FGFR inhibitor for solid tumours, BAY 1163877, which unusually assesses patient suitability based on mRNA expression.

He describes results of the dose escalation study, which tested five doses ranging from 50–800 mg BID (twice daily), and anticipates further based on expansion cohorts already tested.

 Read the news coverage here.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation